AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02217852
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doses used range from 12.5-25mg po qd. Total duration would be until completion or study or medication intolerance.
Trial: NCT00004500
Drug: Lucinactant
RxNorm normalized name: Lucinactant
DrugBank: Lucinactant (DB04897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant's body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.
Trial: NCT00627926
Drug: Telaprevir
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 375 mg tablets administered orally every 8 hours at a dose of 750 mg
Trial: NCT00627926
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing ≥75 kg
Trial: NCT04464408
Drug: Favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily
Trial: NCT00288444
Drug: Lonafarnib
RxNorm normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00288444
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00778349
Drug: Metformin solution 100 mg/mL
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03381859
Drug: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
RxNorm normalized name: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hepatitis C Virus direct-acting antiviral
Trial: NCT02468999
Drug: human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01109134
Drug: tirofiban intracoronary bolus-only
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administer tirofiban bolus intracoronary during primary percutaneous coronary intervention with no additional maintenance infusion
Trial: NCT02273180
Drug: Humalog
RxNorm normalized name: HumaLOG
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Humalog 100 U/mL (dose range of 1 unit to 60 units) self-administered by deep SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycaemia.
Trial: NCT02273180
Drug: Insulin glargine HOE901
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
Trial: NCT01109134
Drug: tirofiban intravenous bolus plus infusion
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administer tirofiban bolus intravenously and maintain infusion for up to 18 hours
Trial: NCT00869128
Drug: Circadin
RxNorm normalized name: ZINC OXIDE 173 mg in 1 mL TOPICAL CREAM [Circadia Circa-Shield Mineral Sunscreen SPF 30]
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg prolonged-release melatonin
Trial: NCT02934555
Drug: Ubiquinol
RxNorm normalized name: Ubiquinol
DrugBank: Ubiquinol (DB11340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg Ubiquinol (3 mL liquid Ubiquinol).
Trial: NCT00362661
Drug: Cortisol
RxNorm normalized name: Cortisol
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cortisol 10 mg/d for 3 months
Trial: NCT01064362
Drug: Fondaparinux sodium
RxNorm normalized name: Fondaparinux Sodium
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)
Trial: NCT00005802
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005802
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005802
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005802
Drug: mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03387657
Drug: Sotagliflozin (SAR439954)
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Trial: NCT03387657
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Trial: NCT00574093
Drug: Ranibizumab; Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be administered Lucentis™ 0.5 mg on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
Trial: NCT00843011
Drug: Orvepitant
RxNorm normalized name: Orvepitant
DrugBank: Orvepitant (DB12427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food.
Trial: NCT00069823
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor 40 mg orally twice daily
Trial: NCT03054285
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants assigned to the experimental arm will receive a seven day course of levetiracetam for post-traumatic brain injury
Trial: NCT03510897
Drug: teprasiran
RxNorm normalized name: Teprasiran
DrugBank: Teprasiran (DB15064)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection
Trial: NCT00500539
Drug: omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The liquid formulation of omalizumab was packaged in a pre-filled safety syringe containing either 75 mg (0.5ml) or 150 mg (1.0 ml) of drug. The syringes were clearly marked so that the health care provider could differentiate between the 75 mg or 150 mg syringe.
Trial: NCT01066871
Drug: Sprifermin (AS902330) 10 mcg
RxNorm normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprifermin (AS902330) will be administered at a dose of 10 microgram (mcg) as intra-articular injection once every week for 3 consecutive weeks.
Trial: NCT01066871
Drug: Sprifermin (AS902330) 30 mcg
RxNorm normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprifermin (AS902330) will be administered at a dose of 30 mcg as intra-articular injection once every week for 3 consecutive weeks.
Trial: NCT01066871
Drug: Sprifermin (AS902330) 100 mcg
RxNorm normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 consecutive weeks.
Trial: NCT01243658
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin
Trial: NCT00305409
Drug: Synbiotic (Synergy I / B.longum)
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01533948
Drug: axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00615810
Drug: Atripla
RxNorm normalized name: Atripla
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open label once daily for oral administration to be taken on an empty stomach
Trial: NCT03606057
Drug: JNJ-64565111
RxNorm normalized name: JNJ-64565111
DrugBank: Efinopegdutide (DB15077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-64565111, subcutaneously on days 2, 9, 16, and 23.
Trial: NCT03606057
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive moxifloxacin capsule on days 1 or 27 in a nested crossover manner.
Trial: NCT03606057
Drug: JNJ-64565111-matching Placebo
RxNorm normalized name: JNJ-64565111
DrugBank: Efinopegdutide (DB15077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-64565111-matching Placebo vehicle solution subcutaneously on days 2, 9, 16, and 23.
Trial: NCT03606057
Drug: Moxifloxacin-matching Placebo
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive moxifloxacin-matching placebo capsule on days 1 and 27 in treatment group 1 and on day 1 or 27 in treatment group 2.
Trial: NCT04003623
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pemigatinib administered orally once daily.
Trial: NCT01997801
Drug: Ketamine infusion
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine will be infused intraoperatively (0.25 mg/kg intravenous bolus following continuous infusion of 100 mcg/kg/hr).
Trial: NCT01997801
Drug: NS infusion
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be infused intraoperatively.
Trial: NCT00001646
Drug: Voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001646
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01673087
Drug: Metyrapone
RxNorm normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 750 mcg, oral, administered twice, 3.5 hours apart
Trial: NCT01673087
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered twice:~1.5 mg, oral, at 11 pm And 0.25 mg, oral, at bedtime at least one week before or after other administration.
Trial: NCT01673087
Drug: Cortrosyn
RxNorm normalized name: Cortrosyn
DrugBank: Tetracosactide (DB01284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mcg, IV, bolus, in the afternoon.
Trial: NCT01673087
Drug: Corticorelin ovine triflutate
RxNorm normalized name: Corticorelin Ovine Triflutate
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg, IV, over 30 seconds, in the afternoon.
Trial: NCT00761371
Drug: Imiquimod 5% cream
RxNorm normalized name: IMIQUIMOD 5% CREAM,TOP,PKT,0.25GM
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.
Trial: NCT00565201
Drug: Botox and rehab
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients will BOTOX® (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
Trial: NCT02232477
Drug: Intrathecal recombinant human alpha iduronidase
RxNorm normalized name: Human Recombinant alpha-L-iduronidase
DrugBank: Laronidase (DB00090)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intrathecal recombinant human alpha iduronidase every 3 months
Trial: NCT00823602
Drug: ganirelix
RxNorm normalized name: Ganirelix
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
Trial: NCT00823602
Drug: suprefact
RxNorm normalized name: Suprefact
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH agonist, standard protocol
Trial: NCT00734656
Drug: dutasteride + placebo alcohol
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg dutasteride administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
Trial: NCT01471444
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flu + Bu Group: 40 mg/m2 by vein on Days -6 through -3.~Flu +Clo + Bu Group: 10 mg/m2 by vein on Days -6 through -3.
Trial: NCT01471444
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 30 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, and infused on Days -6 through -3.
Trial: NCT01471444
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan systemic exposure dose of 6000 µMol-min in normal saline over three (3) hours by vein every twenty-four (24) hours for four (4) consecutive days (days -6 to -3), starting immediately after the completion of Clofarabine. The dose on day -6 to -3 based on pharmacokinetic analysis of target AUC of 4,000 µMol-min ± 5% for 61-70 years of age (without Pharmacokinetics alternate dose 130 mg/m2).
Trial: NCT01471444
Drug: Thymoglobulin
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups who receive a graft from an unrelated donor:~0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1. On day -3, administered after the chemotherapy is complete.
Trial: NCT01471444
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose: 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
Trial: NCT02016911
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
Trial: NCT04508647
Drug: Ublituximab
RxNorm normalized name: Ublituximab
DrugBank: Ublituximab (DB11850)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ublituximab will be administered as an intravenous infusion through a dedicated line. All infusions will be administered per institutional guidelines.~During ublituximab monotherapy (initial treatment), Cycle 1 Day 1 administration time frame: Over 4 hours. Cycle 1 days 8 and 15 will be over 3 hours, and Cycle 1 Day 22 will be over 90 minutes. During combination treatment with umbralisib, ublituximab will be administered over 90 minutes.
Trial: NCT04508647
Drug: Umbralisib
RxNorm normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Umbralisib will be administered orally once daily within 30 minutes of starting a meal.
Trial: NCT03915626
Drug: Rivastigmine (RLD) transdermal patch
RxNorm normalized name: rivastigmine Transdermal Product
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: brand name patch
Trial: NCT03915626
Drug: Rivastigmine (generic) transdermal patch
RxNorm normalized name: rivastigmine Transdermal Product
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: generic patch
Trial: NCT01863719
Drug: Colistimethate sodium
RxNorm normalized name: Colistimethate Sodium
DrugBank: Colistimethate (DB01111)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosol: In Dosing period 2 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses in combination with 3.3mg/kg colistin base activity IV every 8 hours x 3 doses.
Trial: NCT01863719
Drug: Colistimethate sodium
RxNorm normalized name: Colistimethate Sodium
DrugBank: Colistimethate (DB01111)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous: In Dosing period 1 subjects receive 3.3mg/kg colistin base activity every 8 hours x 3 doses (total exposure 10mg/kg) intravenously (IV) followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 3.3mg/kg colistin base activity IV every 8 hours x 3 doses in combination with 75mg colistin base activity via aerosol every 6 hours x 4 doses.
Trial: NCT03208894
Drug: Furosemide Injection
RxNorm normalized name: furosemide Injection
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: efficacy of salbutamol and furosemide in TTN
Trial: NCT00060372
Drug: ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00060372
Drug: therapeutic allogeneic lymphocytes
RxNorm normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03323697
Drug: Escitalopram Pill
RxNorm normalized name: escitalopram Pill
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg capsule plus 5 placebo capsules
Trial: NCT01677182
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramelteon tablets for sublingual administration
Trial: NCT00280514
Drug: cefpirome and moxifloxacin administration
RxNorm normalized name: Cefpirome
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03803163
Drug: TransCon Treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01285778
Drug: panitumumab, mytomicin C, 5-FU, radiation
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Radiation therapy will be administered concurrent with chemotherapy and Panitumumab treatment. It will start the day 1 of the systemic treatment. That is, the first day of radiation therapy will be the day of the administration of the first dose of Panitumumab and Mitomycin C, as well as the first day of the first 96-hours course of 5-FU continuous infusion. On day 1, drugs and radiation will be administered in the following order:~* First, Panitumumab. Panitumumab will be administered by IV infusion on day 1, and every 2 weeks during 8 weeks~* Then Mitomycin C, 10mg/m2 on days 1 and 29~* Then start the 5-FU continuous infusion, 1000mg/m2 on days 1-4 and 29-32~* Finally, no less than 2 hours after the start of the 5-FU infusion, first dose of radiation therapy.
Trial: NCT00616876
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Babies in the study group received lactulose in a dose of 1% in their entire mother's breast milk or preterm formula feeds (1 gram per 100 ml feeds, based on the daily volume of feeds, and evenly distributed between all the feeds for the entire duration of their hospital stay). 67% lactulose in the original preparation (Laevolac, Fresenius Kabi, Austria) was diluted by distilled water to 33.5% preparation in the pharmacy in strict sterile conditions under hood. Just before feeding the nurses added the required volume of this 33.5% lactulose solution to the ordered volume of feed to generate a final concentration of 1% lactulose in each feed.
Trial: NCT03343366
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days
Trial: NCT01314027
Drug: Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with resectable cytologically proven adenocarinoma of the pancreatic head are randomized to arm A or B.~Patients randomized to arm A receive an 8-week neoadjuvant chemotherapy with gemcitabine/oxaliplatin. Thereafter, surgery is performed if the restaging does not reveal a contraindication. Finally, all patients receive adjuvant gemcitabine for six months.
Trial: NCT01314027
Drug: adjuvant chemotherapy with gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients randomized to arm B undergo surgery and receive the same adjuvant treatment as in arm A.